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Abstract. Background: Chronic graft versus host disease (cGVHD) occurs in 20-30% of 
paediatric patients receiving haemopoietic stem cell transplantation (HSCT). Neuromuscular 
disorders such as polymyositis are considered a rare and distinctive but non-diagnostic 
manifestation of cGVHD and, in the absence of other characteristic signs and symptoms, biopsy 
is highly recommended to exclude other causes.  
Case report: We report a case of a 17-months-old child affected by hemophagocytic 
lymphohistiocytosis who underwent a matched unrelated donor haematopoietic stem cell 
transplantation (HSCT). She developed severe cGVHD-related polymyositis that was 
successfully treated with high-dose steroid therapy, rituximab and sirolimus.  
Conclusions: This is the first case of cGVHD-related-polymyositis described in a pediatric 
patient which was successfully treated with rituximab. 
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Introduction. Chronic graft-versus-host-disease 
(cGVHD) is a late complication of allogeneic 
haemopoietic stem cell transplantation (HSCT), 
occurring more than 100 days after transplantation.1 It 
occurs in 20-30% of patients receiving HSCT with 
higher frequency in patients with acute graft-versus-
host-disease (aGVHD).2-4 Early or delayed 
neurological GVHD-related manifestations occur in 
30-60% of allogenic HSCT recipients.5,6 These include 
immune-mediated polyneuropathies and less frequently, 
polymyositis, myasthenia gravis, myositis, 
demyelination, cerebrovascular complications and 
immune-mediated encephalitis.5,6 We report the case of 
a 17-month-old child with an immune-mediated 
myopathy as a consequence of cGVHD-related 
polymyositis. 
 
Case Report. A one-month-old girl of African origin 
was admitted to the local emergency pediatric unit for 
high fever, trilineage blood cytopenia and 
hepatosplenomegaly. Natural killer cells analysis 
showed a lack of perforin expression. The diagnosis of 
hemophagocytic lymphohistiocytosis (HLH) was 
confirmed by Next Generation Sequencing (NGS) 
analysis on peripheral blood DNA, showing the 
presence of genomic variants c.50delT and c.1130G>A 
 
  www.mjhid.org Mediterr J Hematol Infect Dis 2020; 12; e2020002                                                         Pag. 2 / 5 
 
in PRF1 gene, both heterozygous. NM_005041 
(PRF1): c.[50delT(;)1130G>A], 
p.[Leu17ArgfsTer34(;)Cys377Tyr]. These variants, 
both homozygous and compound heterozygous, are 
described as related to HLH.7,8 The patient started 
treatment with dexamethasone and cyclosporine, 
followed by emapalumab, a monoclonal antibody anti-
interferon gamma.9 She underwent HLA-matched 
unrelated donor HSCT at the age of 6 months (HLA-A, 
DRB1, permissive DPB1 allele mismatches). 
Conditioning regimen: busulfan (3x3,2 mg/kg/day), 
fludarabine (3x50 mg/m2/day), thiotepa (2x5 
mg/kg/day) and rabbit antithymocyte globulin (ATG 
GenzymeTM) (3x4,5 mg/kg/day). The patient received 
4.14x108/kg bone marrow total nucleated cells and 
7.37x106/kg of CD34+ cells. GVHD prophylaxis was 
based on cyclophosphamide (2x50 mg/kg) and 
cyclosporine and low dose of prednisone (0,4 
mg/kg/die). The pre-engraftment period was 
complicated by Pseudomonas aeruginosa sepsis (day + 
10) and right lobar pneumonia (day +13). The 
engraftment occurred at day +16 with no sign of 
aGVHD. Therapy with ciclosporin was interrupted 
three months after HSCT, and she started therapy with 
tacrolimus. The prednisone given as GVHD 
prophylaxis was interrupted at month +7 post-HSCT. 
Full donor chimerism was found at day +50 and 
confirmed at month +8 post-HSCT.  At 17 months the 
child was admitted to the hospital for lack of appetite, 
elevated liver enzymes with alanine aminotransferase 
(ALT) 850 U/L and aspartate aminotransferase (AST) 
499 U/L (normal value 5-45), and polypnea. Presuming 
GVHD-related symptoms, she was treated with 
methylprednisolone at the dose of 2 mg/kg/die with no 
clinical improvement. The child rapidly developed 
respiratory failure that required mechanical ventilation. 
An extensive diagnostic work-up was performed: blood 
analysis revealed an increased value of creatine kinase 
(CK) of 13830 U/L (normal value 25-190), creatine 
kinase (CK)-MB 555 ng/L (normal value < 6) and 
troponin of 2601 ng/L (normal value < 45); tacrolimus 
through blood level was in range; immunoglobulin 
levels were normal whilst the peripheral blood 
lymphocyte subpopulations showed an increase in the 
content of B-lymphocytes (2544,34 cells/ul, normal 
value 123-349); echocardiography showed a normal 
biventricular function; electroencephalography (EEG) 
revealed no abnormality; serological test and 
polymerase chain reaction (PCR) assay revealed no 
evidence of recent parvovirus B19, Adenovirus, 
Enterovirus, Cytomegalovirus, Human herpesvirus 6, 
Human immunodeficiency virus, hepatitis B virus, 
hepatitis C virus or Epstein-Barr virus infection; 
cerebrospinal fluid (CSF) findings resulted negative for 
bacterial and viral infections; electromyography 
(EMG) showed a normal pattern of the motor unit 
action potential (MUAP) waveform with normal values 
of F wave and only sporadic myopathic MUAPs were 
found; an extensive screen for autoantibodies related to 
autoimmune and neuromuscular disease was negative. 
In suspicion of a GVHD-related myositis, a biopsy 
from vastus lateralis muscle was performed showing 
necrotic and degenerating muscle fibres, basophilic 
regenerating fibres and inflammatory infiltrates 
predominantly around vessels (Figure 1). 
Inflammatory cells were predominantly composed 
of CD3+ CD8+ T cells; some CD4+ T cells and a few 
CD68+ macrophages, CD20+ B cells and CD57+ 
natural killer cells were observed; only rare CD 138+ 
cells were present (Figure 2). 
These findings indicated immune-mediated 
polymyositis; therefore the immunosuppression 
treatment was potentiated with methylprednisolone 30 
mg/kg for three days, rituximab (105 mg/m2 once 
weekly for four doses); tacrolimus was replaced with 
sirolimus because of its potential neurotoxicity. In the 
 
 
Figure 1.  Light microscopy of muscle biopsy. Hematoxylin and eosin stain shows necrotic, degenerating and regenerating muscle fibers 
(A) and a large inflammatory infiltrate around vessels (B). ATPase reactions showed normal differentiation and distribution of muscle fibers 
and no increase of perimysial or endomysial connective tissue was observed. All other histochemical stains were normal.  
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Figure 2. Immunohistochemistry of muscle biopsy. Serial muscle fiber sections (hematoxylin and eosin) showing mononuclear 
inflammatory cells (A) which are predominantly composed of CD8+ T cells (B); a few CD4+ T cells (C) and CD57+ NK cells (D), and rare 
CD68+ macrophages (E) and CD20+ B cells (F). Major histocompatibility complex (MHC) class I antigen was upregulated on the 
sarcolemma of many muscle fibers and membrane attack complex (MAC) deposits were detected on the wall of few capillaries. 
 
following days the clinical conditions of the child 
improved, with a decrease in CK, CK-MB, AST, ALT 
and troponin values; she was weaned from mechanical 
ventilation after 25 days. In the following weeks the 
girl presented a progressive clinical improvement with 
complete normalisation of the neuromuscular disease 
in about two months. The girl was treated with 
sirolimus (ongoing), and low dose of prednisone (0,2 
mg/kg/die) gradually tapered off over nine months. 
Currently, after 15 months, the girl is asymptomatic in 
very good general conditions without any 
neuromuscular alteration. The values of CK-MB, AST, 
ALT and troponin are average while CK persists 
slightly abnormal (1.5 times above the normal upper 
range). 
 
Discussion. Polymyositis is a sign of cGVHD1,10,12-15 
although not a frequent manifestation, the incidence 
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being approximately 3.4-7.7%.1,5 Host-reactive donor 
lymphocytes are the cells responsible for muscle 
damage involving preferentially and symmetrically the 
proximal muscle groups. Most of the cases reported in 
the literature concern adults1,17 and only a few cases are 
described in children.10-13 This case is the earliest age 
of onset reported, and from a literature review it is the 
only one diagnosed among paediatric allogeneic HSCT 
performed from 2012 to 2018. It is interesting to point 
out that this case occurred in a patient with HLA allele 
mismatch on loci A, DRB1, DPB1 that induced to 
potentiate the regimen of GVHD prophylaxis with the 
use of post-transplant cyclophosphamide. Clinical 
features are similar to those of idiopathic polymyositis, 
involving bilateral muscular weakness of proximal 
muscles while lower extremities are less frequently 
involved.6 Muscular pain is not always present whilst 
heart involvement has been reported.1,5 In our patient, 
as reported in literature6,14 the symptoms appeared after 
the tapering or withdrawal of immunosuppression 
therapy. Laboratory tests show elevated CK (5-50 
times above normal) in most patients, as in our case,  
however CK may be normal or slightly increased in 
clinically stable patients.5,6 Unlike idiopathic 
polymyositis the presence of myositis-specific 
antibodies is rarely positive.6 EMG shows the typical 
myopathic pattern5 although in some cases it may be 
normal,14 as described in our patient. GVHD-related 
polymyositis has been reported to respond to 
corticosteroids alone or in combination with 
cyclosporine, mycophenolate mofetil, methotrexate or 
cyclophosphamide.14 Due to the rarity of this 
manifestation and the complexity of differential 
diagnosis, biopsy has a key role in confirming the 
diagnosis. The typical histopathology examination 
showed segmental muscle fibre necrosis, muscle fibre 
regeneration and mononuclear cell inflammation. 
Generally, immunohistochemistry shows cytotoxic 
CD8+ T donor cell infiltration of endomysium and 
CD4+ and CD8+ T cell infiltration of the perimysium.5 
We found B-lymphocytes (CD20+ cells) infiltration in 
the muscle that correlated with the abnormally high 
number of CD20+ cells on peripheral blood. This 
finding suggested a treatment based on the combination 
of high-dosed methylprednisolone together with 
rituximab, whereas tacrolimus was replaced by 
sirolimus because of some anecdotal cases of 
tacrolimus-related myositis.16 A biopsy with B-cell 
infiltration has already been described in literature, and 
the therapy with rituximab has been shown to be 
effective in adult patients.17-19 This case of cGVHD-
related-polymyositis is the first described in a pediatric 
patient who was successfully treated with rituximab. A 
lower dose was used, if compared to other cases (105 
mg/m2 versus 375 mg/m2),20 thus reducing the possible 
risks due to immunosuppression.  
 
Conclusions. In conclusion, in a patient undergoing 
HSCT with myalgia and muscle weakness even 
without other signs of cGVHD, it is crucial to exclude 
a myopathy secondary to steroid treatment, a 
myasthenia gravis or a viral myopathy.20 The cGVHD-
related polymyositis is a rare condition, but it has to be 
suspected and confirmed with EMG and muscle 
biopsy.20 This condition can be treated, in addition to 
steroid therapy, with rituximab, in particular if the 
muscle biopsy demonstrates B-cell infiltration. 
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